Accumulate evidence demonstrated that CDKN2A is common in cerebrospinal fluid (CSF) samples of lung adenocarcinoma patients with central nervous system (CNS) metastases, and concurrent CDKN2A with EGFR-sensitive mutations indicated inferior median intracranial PFS (iPFS). Here, EGFR is linked to lung adenocarcinoma.